Marshall Wace, LLP Arvinas, Inc. Transaction History

Marshall Wace, LLP

$78.4 Billion
Q4 2024

A detailed history of Marshall Wace, LLP transactions in Arvinas, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 268,026 shares of ARVN stock, worth $4.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

268,026

Previous 170,350 57.34%

Holding current value

$4.9 Million

Previous $4.2 Million 22.48%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$17.83 - $28.04 $1.74 Million - $2.74 Million	97,676 Added 57.34%	268,026 $5.14 Million
Q3 2024 Nov 14, 2024	BUY	$23.66 - $32.73 $3.55 Million - $4.91 Million	150,150 Added 743.32%	170,350 $4.2 Million
Q2 2024 Aug 14, 2024	BUY	$24.46 - $40.4 $494,092 - $816,080	20,200 New	20,200 $537,000
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $667,866 - $1.99 Million	47,066 New	47,066 $1.94 Million
Q2 2023 Aug 14, 2023	BUY	$21.73 - $31.43 $463,587 - $670,527	21,334 Added 222.93%	30,904 $767,000
Q1 2023 May 15, 2023	BUY	$26.15 - $37.26 $250,255 - $356,578	9,570 New	9,570 $261,000
Q2 2022 Aug 15, 2022	SELL	$36.01 - $74.24 $17.1 Million - $35.3 Million	-475,927 Reduced 93.11%	35,220 $1.48 Million
Q2 2021 Aug 13, 2021	SELL	$60.45 - $84.26 $21.5 Million - $30 Million	-356,110 Reduced 41.06%	511,147 $39.4 Million
Q1 2021 May 17, 2021	BUY	$58.19 - $91.37 $241,488 - $379,185	4,150 Added 0.48%	867,257 $57.3 Million
Q4 2020 Feb 16, 2021	BUY	$20.19 - $84.93 $15.5 Million - $65.1 Million	766,932 Added 797.43%	863,107 $73.3 Million
Q3 2020 Nov 16, 2020	BUY	$22.99 - $36.34 $1.35 Million - $2.13 Million	58,728 Added 156.83%	96,175 $2.27 Million
Q2 2020 Aug 13, 2020	BUY	$29.88 - $56.74 $1.12 Million - $2.12 Million	37,447 New	37,447 $1.26 Million

Others Institutions Holding ARVN

# of Institutions

224

Shares Held

70.9M

Call Options Held

1.52M

Put Options Held

346K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $973M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Arvinas, Inc. Transaction History